Modality
Radioligand
MOA
CDK4/6i
Target
BET
Pathway
Angiogenesis
MCLEwing Sarcoma
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
Jun 2018
→ Jul 2029
Phase 1Current
NCT04234271
2,015 pts·MCL
2023-07→2029-07·Terminated
NCT04861455
2,825 pts·MCL
2018-06→2029-06·Completed
4,840 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-06-023.2y awayPh2 Data· MCL
2029-07-233.3y awayPh2 Data· MCL
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Complet…
P1/2
Termina…
Catalysts
Ph2 Data
2029-06-02 · 3.2y away
MCL
Ph2 Data
2029-07-23 · 3.3y away
MCL
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04234271 | Phase 1/2 | MCL | Terminated | 2015 | HAM-D |
| NCT04861455 | Phase 1/2 | MCL | Completed | 2825 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| NBI-3153 | Neurocrine | Approved | Aβ | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF |